According to KFF analysis of Centers for Medicare & Medicaid Services 2018-2022 Medicare Part D spending by drug increased from $57 Million to $5.7 Billion.[2] The June 13, 2024 article in Fierce Healthcare[3] on GLP-1 drugs noted that Blue Cross Blue Shield of Michigan will no longer cover these drugs starting in January 2025, and will be changing the prior authorization criteria starting in August 2024, for those members that are in large group fully insured commercial plans
[/vc_column_text][/vc_column_inner][/vc_row_inner][stm_post_tags][stm_post_comments][stm_spacing lg_spacing=80 md_spacing=80 sm_spacing=30 xs_spacing=20][/vc_column][vc_column width=1/3 offset=vc_hidden-sm vc_hidden-xs][stm_share_buttons][stm_sidebar sidebar=1469][/vc_column][vc_column width=1/3][/vc_column][/vc_row]
When administered, B12 injections allow the vitamin to enter the body efficiently and support the bodys natural processes that rely on adequate B12 levels
TB-500 (Ac-Fragments) 1250 mcg
It supports collagen synthesis, the formation of new blood vessels (angiogenesis), and the immune response, all of which are essential for proper wound healing
